AMENDMENTS TO THE CLAIMS

1-18. (canceled)

19. (currently amended) A composition for ~~induction of a~~ induction of cytotoxic T ~~lymphocyte response~~ lymphocytes that lyse cancer cells upon recognition of naturally processed human telomerase reverse transcriptase peptides, comprising: at least one HLA-A2.1-restricted, human telomerase reverse transcriptase (TRT) peptide ~~from seven to fifteen~~ nine amino acid residues in length of a human TRT protein consisting of a sequence set forth in SEQ ID NO:23, and a physiologically acceptable carrier.

20. (canceled)

21. (previously presented) The composition of claim 19, wherein said at least one TRT peptide consists of a peptide with a sequence set forth as SEQ ID NO:1.

22. (previously presented) The composition of claim 19, wherein said at least one TRT peptide consists of a peptide with a sequence set forth as SEQ ID NO:2.

23. (canceled)

24. (previously presented) The composition of Claim 19, further comprising a helper peptide consisting of a peptide with a sequence set forth as SEQ ID NO:4.

25. (previously presented) The composition of Claim 24, wherein said helper peptide is not conjugated to said TRT peptide.

26. (currently amended) A composition for induction of cytotoxic T lymphocytes that lyse cancer cells upon recognition of naturally processed human telomerase reverse transcriptase peptides, comprising: at least one human telomerase reverse transcriptase (TRT) peptide ~~from seven to fifteen~~ nine amino acid residues in length of a human TRT protein consisting of a sequence set forth in SEQ ID NO:23, wherein said TRT peptide comprises a modification to enhance binding to HLA-A2.1.

27. (previously presented) The composition of claim 26, further comprising a helper peptide consisting of a peptide with a sequence set forth as SEQ ID NO:4.

28. (previously presented) The composition of Claim 26, wherein said modification is a tyrosine substitution.

29. (previously presented) The composition of Claim 28, wherein said tyrosine substitution is at position 1 of a canonical HLA-A2.1 motif.

30-31. (canceled)

32. (previously presented) The composition of Claim 28, wherein said TRT peptide is SEQ ID NO:22.

33. (previously presented) The composition of Claim 28, further comprising an adjuvant.

34. (previously presented) The composition of Claim 28, further comprising a physiologically acceptable carrier.

35. (previously presented) The composition of Claim 34, wherein said carrier is a mammalian cell.

36. (new) The composition of Claim 19, wherein said at least one TRT peptide consists of a peptide with a sequence set forth as SEQ ID NO:16.

37. (new) A composition for induction of cytotoxic T lymphocytes that lyse cancer cells upon recognition of naturally processed human telomerase reverse transcriptase peptides, comprising: at least one HLA-A2.1-restricted, human telomerase reverse transcriptase (TRT) peptide and a physiologically acceptable carrier, wherein said human TRT peptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:16.

38. (new) The composition of Claim 37, wherein said human TRT peptide is SEQ ID NO:1.

39. (new) The composition of Claim 37, wherein said human TRT peptide is SEQ ID NO:2.

40. (new) The composition of Claim 37, wherein said human TRT peptide is SEQ ID NO:16.

41. (new) A composition for induction of cytotoxic T lymphocytes that lyse cancer cells upon recognition of naturally processed human telomerase reverse transcriptase peptides, comprising: at least one human telomerase reverse transcriptase (TRT) peptide comprising a modification to enhance binding to HLA-A2.1, and a physiologically acceptable carrier, wherein said human TRT peptide is SEQ ID NO:22.